Eur Rev Med Pharmacol Sci 2019; 23 (5): 2167-2173

DOI: 10.26355/eurrev_201903_17262

Lipid accumulation product and visceral adiposity ındex: two new indices to predict metabolic syndrome in chronic kidney disease

Z. Biyik, I. Guney

Nephrology Department, Health Science University, Konya Research and Training Hospital, Konya, Turkey. drzeynepbiyik@gmail.com


OBJECTIVE: The aim of this study was to assess the ability of lipid accumulation product (LAP) and visceral adiposity index (VAI) to predict metabolic syndrome (MetS) in patients with chronic kidney disease (CKD). We also aimed to determine whether VAI and LAP indices are superior to traditional body indices such as body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR).

PATIENTS AND METHODS: This study was performed by retrospectively scanning the files of patients with stage 3-5 chronic renal failure who came for nephrology outpatient follow-up between January 2017 and December 2017. Metabolic syndrome was identified using the 2009 harmonized criteria. The receiver operating characteristic curve (ROC) was used to compare the area under the ROC curve (AUC) of each index.

RESULTS: 247 patients were included in the analyses. The prevalence of MetS was 80.9%. LAP was determined as the optimal predictor in chronic kidney disease patients, with 0.864 AUC in females and 0.908 AUC in males. Optimal cut-off values for LAP were 33.5 in females and 36.6 in males. VAI was the second most optimal predictor, with 0.856 AUC in females and 0.888 AUC in males. Optimal cut-off values for VAI were 2.24 in females and 1.56 in males.

CONCLUSIONS: LAP and VAI are effective indices for the prediction of MetS in patients with chronic kidney disease; LAP is the best index for the determination of MetS in both men and women.

Free PDF Download

To cite this article

Z. Biyik, I. Guney
Lipid accumulation product and visceral adiposity ındex: two new indices to predict metabolic syndrome in chronic kidney disease

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 5
Pages: 2167-2173
DOI: 10.26355/eurrev_201903_17262